Holen Sie sich die Stockscreener-App
1.38
4.83%
-0.07
Handel nachbörslich:
1.38
Schlusskurs vom Vortag:
$1.45
Offen:
$1.41
24-Stunden-Volumen:
1.61M
Relative Volume:
1.01
Marktkapitalisierung:
$159.19M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.8364
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-11.54%
1M Leistung:
+31.43%
6M Leistung:
+36.63%
1J Leistung:
+52.47%
1-Tages-Spanne:
$1.34
$1.43
1-Wochen-Bereich:
$1.332
$1.60
52-Wochen-Spanne:
$0.6611
$1.9399
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.38 | 167.26M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire
Fate Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
FATE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Growth Value: Is Fate Therapeutics Inc subject to activist investor interestQuarterly Market Summary & High Return Trade Opportunity Guides - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE) - The Globe and Mail
Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations - MarketBeat
Fate Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Baird reiterates Fate Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Fate Therapeutics: Fourth Quarter Earnings Overview - Bitget
Biotechnology company Fate Therapeutics Inc announced that its current cash reserves are sufficient to sustain company operations until the end of 2027. - Bitget
FATE THERAPEUTICS INC SEC 10-K Report - TradingView
Fate Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - The Manila Times
Fate Therapeutics reports lower Q4 collaboration revenue - TradingView
Form 10-K FATE THERAPEUTICS INC For: Dec 31 - StreetInsider
Earnings Summary: Fate Therapeutics Q4 - Benzinga
Fate Therapeutics (NASDAQ: FATE) cuts 2025 expenses, extends cash runway - Stock Titan
Off-the-shelf CAR-T goes outpatient as Fate cuts hospital stays, chemo - Stock Titan
Fate Therapeutics FY 2025 Loss Reduction Tests Bullish Narratives On Path To Profitability - Sahm
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Bond Watch: What are AFBIs technical support levels2025 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
Aug Patterns: Will Fate Therapeutics Inc outperform small cap indexes2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Fate Therapeutics (FATE) to Release Earnings on Wednesday - MarketBeat
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
Will Fate Therapeutics Inc. outperform the market in YEARTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru
Is Fate Therapeutics Inc. stock risky to hold now2025 Geopolitical Influence & Advanced Technical Signal Analysis - mfd.ru
Is Fate Therapeutics Inc. subject to activist investor interestJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
MSN Money - MSN
Can Fate Therapeutics Inc. lead its sector in growthJuly 2025 Technicals & Fast Entry and Exit Trade Plans - mfd.ru
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GuruFocus
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
What analysts say about Fate Therapeutics Inc. stock2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru
FATE PE Ratio & Valuation, Is FATE Overvalued - Intellectia AI
S P Trends: What analysts say about Fate Therapeutics Inc stock2025 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Gains Recap: Can Fate Therapeutics Inc lead its sector in growthMarket Movers & Community Verified Watchlist Alerts - baoquankhu1.vn
The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average – What’s Next? - Defense World
Nasdaq Moves: What is the dividend yield of Fate Therapeutics IncMarket Performance Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Loss Report: Can Fate Therapeutics Inc ride the EV waveVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode? - AD HOC NEWS
Guidance Update: What analysts say about Fate Therapeutics Inc stock2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat
Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened - Defense World
Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results - IT Business Net
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):